📰 Curated Industry Article
This is a summary of a full article from a trusted healthcare and insurance publication. Click “Read Full Article” below to read the complete story.
Roche reported the drug sefaxersen achieved statistically significant and clinically meaningful results in a Phase 3 test in immunoglobulin A nephropathy, or IgAN. This antisense oligonucleotide, which came from Ionis Pharmaceuticals, could offer advantages over other drugs currently available for treating this rare chronic disease of the kidneys.
The post Phase 3 Data Could Make Roche Drug a Contender to Treat Rare Kidney Disease` appeared first on MedCity News.
💡 What This Means For You
[armfox_dynamic_insight]
ARMFOX HEALTHCARE
Stay Informed. Protect Your Future.
No pressure. No jargon. Just honest answers from advisors who genuinely care about your family’s protection.
📰 This article is sourced from a trusted healthcare and insurance industry publication. Armfox Healthcare shares this for informational purposes only. Always consult a licensed advisor for personalized guidance.